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Abstract
Recent advances in the neurobiology of cannabinoids have renewed interest in the association between
cannabis and schizophrenia. Our studies showed that chronic-intermittent phencyclidine (PCP) treatment
of rats, an animal model of schizophrenia-like cognitive deﬁcit, impaired recognition memory in the novel
object recognition (NOR) test and induced alterations in CB1 receptor functionality and in endo-
cannabinoid levels mainly in the prefrontal cortex. In this region, we observed a signiﬁcant reduction in
GTPcS binding (x41%) accompanied by an increase in the levels of the endocannabinoid 2-AG (+38%) in
PCP-treated rats, suggesting that a maladaptation of the endocannabinoid system might contribute to the
glutamatergic-related cognitive symptoms encountered in schizophrenia disorders. Moreover, we evalu-
ated the ability of the main psychoactive ingredient of marijuana, D9-tetrahydrocannabinol (THC), to
modulate the cognitive dysfunctions and neuroadaptations in the endocannabinoid system induced by
PCP. Chronic THC co-treatment worsened PCP-induced cognitive impairment, without inducing any
eﬀect per se, and in parallel, it provoked a severe reduction in the levels of the other endocannabinoid,
AEA, vs. either vehicle (x73%) or PCP (x64%), whereas it reversed the PCP-induced increase in 2-AG
levels. These results point to the involvement of the endocannabinoid system in this pharmacological
model of cognitive dysfunction, with a potentially diﬀerent role of AEA and 2-AG in schizophrenia-like
behaviours and suggest that prolonged cannabis use might aggravate cognitive performances induced by
chronic PCP by throwing oﬀ-balance the endocannabinoid system.
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Introduction
Cannabis sativa is one of the most frequently abused
substances among schizophrenia patients (Jablensky
et al., 1992). Although some researchers have inter-
preted this phenomenon as a method of self-therapy
for counterbalancing negative symptoms of schizo-
phrenia or side-eﬀects of antipsychotic treatment
(Dixon et al., 1991 ; Krystal et al., 1999), recent meta-
analyses of epidemiological studies seem to suggest
that cannabis use could be a risk factor or contributory
cause for developing psychoses (Degenhardt and Hall,
2006 ; Hall and Degenhardt, 2006 ; Henquet et al., 2005 ;
Semple et al., 2005). However, the presence of a re-
lationship between the endocannabinoid system and
schizophrenia is corroborated by several observations.
First, CB1 receptors are mainly distributed in areas of
the human brain implicated in schizophrenia, includ-
ing prefrontal cortex, anterior cingulate cortex, basal
ganglia, and hippocampus (Herkenham et al., 1990) ;
post-mortem studies have shown alterations in CB1
receptor densities in the prefrontal and anterior/
posterior cingulate cortices of schizophrenia patients
compared to normal controls (Dean et al., 2001 ;
Newell et al., 2006 ; Ujike andMorita, 2004 ; Zavitsanou
et al., 2004). Anandamide levels are abnormally
elevated in the cerebrospinal ﬂuid and plasma of
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schizophrenia patients (De Marchi et al., 2003;
Giuﬀrida et al., 2004 ; Leweke et al., 1999, 2007) and
appear to be inversely correlated with psychotic
symptoms, suggesting a compensatory adaptation to
the disease state (DeMarchi et al., 2003 ; Giuﬀrida et al.,
2004). Last, an association between CB1 receptor gene
polymorphisms and schizophrenia has been reported
(Leroy et al., 2001).
In light of this multifaceted background it is of great
interest to investigate the eﬀects of the pharmacologi-
cal modulation of the cannabinoid system in diﬀerent
experimental animal models of schizophrenia repro-
ducing positive, negative or cognitive symptoms of
the disease. Generally, CB1 receptor agonists reduce
the hyperlocomotion induced by amphetamine, quin-
pirole and cocaine (Gorriti et al., 1999; Marcellino et al.,
2008 ; Moreira and Guimara˜es, 2005 ; Przegalin´ski et al.,
2005), although not always by acting via CB1 re-
ceptors ; CB1 antagonists can reduce, increase or not
aﬀect the hyperlocomotion induced by diﬀerent
dopaminergic agents (Corbille´ et al., 2007 ; Ferrer et al.,
2007 ; Madsen et al., 2006; Masserano et al., 1999;
Poncelet et al., 1999). Moreover, CB1 gene deletion re-
duces the hyperlocomotion induced by both dopami-
nergic agents and phencyclidine (PCP) (Corbille´ et al.,
2007 ; Haller et al., 2005). Regarding sensory motor
information gating processes, generally CB1 receptor
agonists disrupt pre-pulse inhibition (PPI) (Bortolato
et al., 2005 ; Hajo´s et al., 2008; Martin et al., 2003;
Schneider and Koch, 2005), whereas cannabidiol
and the CB1 receptor antagonist, SR141716A, reverse
MK801- or PCP-induced PPI deﬁcit (Ballmaier et al.,
2007 ; Long et al., 2006 ; but see also Martin et al., 2003).
In contrast, to the best of our knowledge there are no
data exploring the ability of cannabinoid compounds
to alter the cognitive deﬁcit associated with schizo-
phrenia. Here we studied the role of the endocan-
nabinoid system and its pharmacological modulation
in a model based on chronic injection of low doses of
PCP (Cochran et al., 2003 ; Pratt et al., 2008), which
produces a speciﬁc pattern of hypometabolism within
the rat prefrontal cortex, thereby reproducing the so-
called ‘hypofrontality ’ that is observed in PCP drug
abusers (Wu et al., 1991) and schizophrenia patients
(Andreasen et al., 1992 ; Tamminga et al., 1992; Wolkin
et al., 1992). We chose a glutamatergic model of
schizophrenia due to the well documented relation-
ship between glutamate and cannabinoid systems.
Several studies have reported that CB1 agonists can
reduce glutamatergic synaptic transmission in several
brain regions involved in the regulation of gating
functions (Auclair et al., 2000 ; Azad et al., 2003;
Fujiwara and Egashira, 2004 ; Misner and Sullivan,
1999 ; Robbe et al., 2001) and the activation of CB1 re-
ceptors is involved in mGluR5 receptor mechanisms of
PCP (Kinney et al., 2005). First, we veriﬁed the cogni-
tive impairment induced by chronic intermittent PCP
exposure by using the Novel Object Recognition
(NOR) test. The NOR is a non-rewarded, ethologically
relevant, relatively simple test based on the natural
propensity of rats to explore novel objects (Bevins and
Besheer, 2006). It has been listed under the TURNS
initiative [Treatment Units for Research on Neuro-
cognition and Schizophrenia (www.TURNS.ucla.edu)]
as relevant for studying learning and memory deﬁcits
in schizophrenia and it is widely used for testing
cognitive deﬁcits in schizophrenia (Fujita et al., 2008;
Grayson et al., 2007 ; Hashimoto et al., 2005). Then, we
evaluated whether chronic PCP treatment per se alters
the endocannabinoid system in terms of CB1 receptor
density and eﬃciency and endocannabinoid levels.
Finally, a chronic treatment with D9-tetrahydrocan-
nabinol (THC) was combined with chronic PCP to
evaluate its inﬂuence on both the cognitive impair-
ment induced by PCP and endocannabinoid system
functionality.
Material and method
Animals
Juvenile Lister-Hoodedmale rats (Harlan, Udine, Italy)
weighing 126–150 g at the time of arrival were used.
Rats were grouped 3–4 per cage and housed on a 12 h
light/dark cycle (lights on 08:00 hours) with food/
water available ad libitum. All experiments were con-
ducted during the light phase and carried out in strict
accordance with the guidelines released by the Italian
Ministry of Health (D.L. 116/92 and D.L. 111/94-B),
and the European Community directives regulating
animal research (86/609/EEC). All eﬀorts were made
to minimize the number of animals used and their
suﬀering.
Drugs
Phencyclidine hydrochloride (PCP, Sigma-Aldrich,
Dorset, UK), was dissolved in saline. THC, a generous
gift from GW Pharmaceutical (Salisbury, UK), was
dissolved in ethanol, cremophor and saline (1 :1 :18).
Clozapine (Sigma, Milan, Italy) was dissolved in a
minimum volume of acetic acid, made up to volume
with distilled water and pH adjusted to 6 with
0.1 m NaOH. The dose and timing of clozapine was
chosen on the basis of previous studies (Grayson
et al., 2007 ; Hashimoto et al., 2005 ; McLean et al.,
2008).
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Treatment regimes
The rats were allowed to acclimate in their new en-
vironment for 1 wk before the start of the treatment.
Chronic-intermittent PCP exposure. Intraperitoneal (i.p.)
injections of PCP (2.58 mg/kg) or saline (1 ml/kg) once
daily according to the procedure of Cochran et al.
(2003) were performed at the time-interval indicated in
Figure 1 (scheme of treatment).
PCP+THC chronic treatment. Chronic treatment with
THC (0.5 mg/kg i.p.) or vehicle was combined with
PCP according to the scheme of treatment in Figure 1.
As positive control in object recognition test, chronic
treatment with clozapine (5 mg/kg i.p.) or vehicle was
combined with PCP according to the scheme of treat-
ment in Figure 1.
Behavioural tests
NOR test
Behavioural testing started 72 h after the end of
chronic treatment (day 29). The experimental appar-
atus used for the object recognition test was an open-
ﬁeld box (in cm, 60 wider60 deepr60 high) made
of Plexiglas, placed in a dimly lit room. On the day
of testing, the animals were habituated in a quiet
laboratory for a 1-h period, before experimental pro-
cedures began. Animals performed each test indi-
vidually. A 10-min habituation session preceded the
experimental trials. In the object recognition task, each
rat was placed into the box and exposed to two
identical objects for a period of 10 min (familiarization
phase). The rats were then returned to their home cage
for a 1-h inter-trial interval, the entire box was cleaned,
both objects removed and one replaced with an
identical familiar copy and one with a novel object.
Following this interval, rats were returned to explore
the familiar and novel objects in the test box for a
3-min test phase.
Object exploration was deﬁned as the rats sniﬃng,
licking or touching the objects with forepaws whilst
sniﬃng but not by leaning against, turning around,
standing or sitting on the objects. The exploration time
of each object in each trial was recorded manually
using two stopwatches and the following factors were
calculated: E1=the total exploration time of both
objects in the familiarization trial (EF1+EF2), E2=the
total exploration time of both objects in the test trial
(EF+EN). The discrimination index (DI) represents
the diﬀerence in exploration time expressed as a pro-
portion of the total time spent exploring the two
objects during the test trial (DI=(ENxEF)/(EN+EF)r
100). The behaviour was also recorded by using
a video camera mounted above the experimental
apparatus. Tapes were analysed oﬄine by a trained
observer who was unaware of the treatment condition.
In an attempt to avoid the presence of olfactory trails,
sawdust was stirred and the objects were thoroughly
cleaned with 0.1% acetic acid after each rat.
For locomotor activity, data were acquired and
analysed by the ANYMZE software (Ugo Basile,
Varese, Italy) using a video camera mounted above the
arena. Using the software, the experimenter drew the
ﬂoor of the apparatus on the computer screen and
divided it into four equal squares. The total number of
line crossings between squares was recorded. These
supplementary analyses are particularly important to
examine when the experimental treatment alters object
recognition (Bevins and Besheer, 2006).
Biochemical assays
Autoradiographic-binding studies
Seventy-two hours after the last injection of PCP and/
or THC, adult rats were decapitated and brains were
rapidly removed and frozen in liquid nitrogen and
stored at x80 xC until processing. Coronal sections
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Figure 1. Treatment schedule. A total of 40 male Lister Hooded rats were randomly assigned to the diﬀerent groups.
Clz, Clozapine ; PCP, phencyclidine ; THC, D9-tetrahydrocannabinol.
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(20 mm) were cut on a cryostat and thaw-mounted on
gelatin-coated slides. The sections were brieﬂy dried at
30 xC and stored atx80 xC until they were processed
for autoradiographic-binding studies.
[3H]CP-55,940 receptor autoradiographic binding
The [3H]CP-55,940 receptor autoradiographic binding
was performed as previously described (Rubino et al.,
1997) and here brieﬂy summarized. Slides were
brought to room temperature, then incubated for 2.5 h
at 37 xC with 10 nM [3H]CP-55,940 (PerkinElmer Life
Sciences, Milan, Italy) in binding buﬀer [50 mM
Tris–HCl (pH 7.4), 5% BSA]. Adjacent cerebral sec-
tions were incubated in parallel with 10 mM CP-55,940
to assess non-speciﬁc binding. Sections were washed
for 1 h at 4 xC in 50 mM Tris–HCl (pH 7.4), 1% BSA
buﬀer and again for 3 h in the same conditions. They
were than dipped in 50 mM Tris–HCl buﬀer (pH
7.4, 5 min) to remove excess BSA, dipped brieﬂy in
distilled water, and dried under a cool air stream.
Autoradiograms were generated by exposing the
dried sections for 7 d to Hyperﬁlm 3H (GE Healthcare,
Milan, Italy).
CP-55,940-stimulated [35S]GTPcS binding in
autoradiography
This was determined as previously described (Rubino
et al., 2000a), with slight modiﬁcations. Brieﬂy, slides
were incubated in assay buﬀer [50 mM Tris–HCl, 3 mM
MgCl2, 0.2 mM EGTA, 100 mM NaCl, 10 mU/adeno-
sine deaminase, 0.1% BSA (pH 7.4)] at 25 xC for 10 min
then in 3 mM GDP in assay buﬀer at 25 xC for 15 min.
They were then transferred to assay buﬀer containing
3 mM GDP and 0.04 nM [35S]GTPcS with (stimulated)
or without (basal) 5 mM CP-55,940 and incubated at
25 xC for 2 h. Slides were rinsed twice in 50 mM cold
Tris buﬀer and once in deionized water, dried, and
exposed to bmax ﬁlm (GE Healthcare) for 48 h.
Image analysis
The intensity of the autoradiographic ﬁlms was as-
sessed by measuring the grey levels with an image
analysis system consisting of a scanner connected
to a PC running Microsoft Windows. The images
were analysed using Image-Pro Plus 5.0 (Media
Cybernetics, Silver Spring, MD, USA) as previously
described. Each area of both sides of the brain was
traced with the mouse cursor using the Paxinos and
Watson (2005) atlas as reference, and light trans-
mittance was determined as the grey level. The
grey level of densitometric measurements calculated
after subtraction of the ﬁlm background density
was established within the linear range, determined
using tritium standards (3H Microscales, Amersham
Pharmacia Biotech, Milan, Italy) for receptor-binding
studies For GTPcS autoradiography, 35S standards
were prepared in the laboratory and agonist-
stimulated activity was calculated by subtracting the
optical density in basal sections (GDP only) from that
of agonist-stimulated sections and results are ex-
pressed as percent stimulation over basal activity, as
previously described (Sim et al., 1996).
Endocannabinoid levels
Lipid extraction and endocannabinoid measurement
Tissue extraction
Tissues were homogenized in 5 vol chloroform/
methanol/Tris–HCl 50 mM (2:1 :1) containing 20 pmol
of d8-AEA, and d5-2-AG. Deuterated standards
were synthesized from d8 arachidonic acid and eth-
anolamine or glycerol, as described, respectively,
in Devane et al. (1992) and Bisogno et al. (1997).
Homogenates were centrifuged at 13 000 g for 16 min
(4 xC), the aqueous phase plus debris was collected
and extracted again twice with 1 vol chloroform.
The organic phases from the three extractions were
pooled and the organic solvents evaporated in a
rotating evaporator. Lyophilized samples were then
stored frozen at x80 xC under nitrogen atmosphere
until analysed.
Analysis of endocannabinoid content
Lyophilized extracts were re-suspended in chloro-
form/methanol 99 :1 by volume. The solutions were
then puriﬁed by open bed chromatography on silica as
described in Bisogno et al. (1997). Fractions eluted
with chloroform/methanol 9 :1 by volume [containing
AEA, 2-AG, and palmitoylethanolamide (PEA)] were
collected, the excess solvent was evaporated with a
rotating evaporator, and aliquots were analysed by
isotope dilution-liquid chromatography/atmospheric
pressure chemical ionization/mass spectrometry
(LC–APCI–MS) carried out under conditions descri-
bed previously (Marsicano et al., 2002), allowing the
separation of 2-AG and AEA. Mass spectrometric (MS)
detection was carried out in the selected ion monitor-
ing mode using m/z values of 356 and 348 (molecular
ions +1 for deuterated and undeuterated AEA) and
384.35 and 379.35 (molecular ions +1 for deuterated
and undeuterated 2-AG).The area ratios between
signals of deuterated and undeuterated AEA varied
602 D. Vigano et al.
linearly with varying amounts of undeuterated AEA
(30 fmol to 100 pmol). The same applied to the area
ratios between signals of deuterated and undeuterated
2-AG in the 100 pmol to 20 nmol interval. AEA and
2-AG levels in unknown samples were therefore
calculated on the basis of their area ratios with the
internal deuterated standard signal areas. For 2-AG,
the areas of the peaks corresponding to 1(3)- and
2-isomers were added together. The amounts of endo-
cannabinoids were expressed as picomoles/milligrams
of lipid extracted.
Statistical analysis
Data are expressed as mean¡S.E.M. Student’s t test was
performed to compare the eﬀect of treatment on the
time spent exploring the two familiar and novel ob-
jects vs. familiar objects. Analyses of the locomotor
activity and DI data were performed using a one-way
ANOVA followed by post-hoc Bonferroni compari-
son. Biochemical data were analysed using Student’s
t test or one-way ANOVA followed by post-hoc
Bonferroni comparison. p values <0.05 were con-
sidered statistically signiﬁcant.
Results
Chronic-intermittent PCP exposure
NOR test
In the NOR test, repeated PCP administration caused a
signiﬁcant cognitive deﬁcit 72 h after the last PCP
injection (Figure 2). Vehicle- and PCP-treated rats
spent equivalent times exploring the identical objects
(left and right) in the familiarization phase (Figure 2a).
During the test phase rats treated subchronically with
vehicle clearly diﬀerentiated the familiar and novel
objects as they spent signiﬁcantly (p<0.001) longer
exploring the novel object compared to the familiar
object (Figure 2c). In contrast, the ability to discrimi-
nate familiar and novel objects was abolished by
chronic PCP treatment. There was no signiﬁcant dif-
ference in exploration of the novel and familiar objects
(Figure 2c) and there was a signiﬁcant reduction
(x90%) in the DI (F3,16=17.01, p<0.0001, p<0.001 for
post-hoc comparison) (Figure 2d). Statistical analysis
revealed no signiﬁcant eﬀect of PCP treatment on
locomotor activity (Figure 2b), as shown by the num-
ber of line crossings.
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Figure 2. Eﬀect of chronic phencyclidine (PCP) (2.58 mg/kg i.p.) on the novel object recognition (NOR) test. Panels (a) and (b)
represent the exploration time of identical objects (a) and the number of line crossing (b) during the familiarization trial. Panels
(c) and (d) represent the exploration time of the familiar vs. novel objects (c) and the discrimination index (d) during the test
phase. The eﬀect of chronic clozapine (Clz, 5 mg/kg i.p.) is reported as positive control. The NOR test was performed 72 h after
the last drugs injection. Data are expressed as the mean¡S.E.M. of at least four animals per group. (c) * p<0.05, *** p<0.001 vs.
familiar object (Student’s t test). (d) *** p<0.001 vs. vehicle ; +++ p<0.001 vs. PCP (one-way ANOVA followed by Bonferroni
post-hoc comparison).
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Chronic treatment with clozapine, an atypical
antipsychotic drug, signiﬁcantly reduced the PCP-
induced impairment in NOR producing a signiﬁcant
increase in time spent exploring the novel object com-
pared with the familiar object (p<0.05) and restoring
the DI (F3,16=17.01, p<0.0001, p<0.001 for post-hoc
comparison) respectively to PCP (Figure 2c, d). Cloz-
apine per se failed to reveal any signiﬁcant treatment
eﬀect.
CB1 receptor functionality
In order to investigate the potential involvement of the
cannabinoid system in the cognitive impairment pro-
duced by PCP, we measured the CB1 receptor levels
and eﬃciency in several brain regions of vehicle-
and PCP-treated rats. In the [3H]CP-55,940 receptor-
binding study, among all the studied brain areas
expressing CB1 receptors, PCP exposure induced a
slight but signiﬁcant enhancement in CB1 receptor
density in the amygdala (+15%, p<0.05) and a
more sustained increase in the ventral tegmental area
(+48%, p<0.01) when compared to the control group
(Figure 3a). CP-55,940-stimulated GTPcS binding re-
vealed a diﬀerent alteration than that observed in the
receptor-binding assay (Figure 3b). In fact, prolonged
exposure to PCP induced signiﬁcant reduction in
the percentage of CB1 net stimulation in the prefrontal
cortex (x41%, p<0.0001), hippocampus (x40%,
p<0.0001), substantia nigra (x29%, p<0.01) and
cerebellum (x39%, p<0.01) and an increase in the
globus pallidus (+77%, p<0.05) when compared to
controls. Basal [35S]GTPcS binding was not aﬀected
by PCP treatment in any of the cerebral areas studied
(data not shown). Representative autoradiograms
containing the amygdala and prefrontal cortex are
shown in Figure 3c.
Endocannabinoid levels
Due to the presence of alterations in CB1 receptor ef-
ﬁciency in brain areas involved in cognitive functions
that might be related to the impairment in NOR (pre-
frontal cortex and hippocampus), we evaluated endo-
cannabinoid levels in these regions (Figure 4). In the
prefrontal cortex of PCP-treated rats, AEA levels were
reduced by about 24% without reaching any statistical
signiﬁcance, whereas 2-AG levels were signiﬁcantly
increased (+38%, p<0.05). Neither AEA nor 2-AG
levels were altered in the hippocampus.
Eﬀect of chronic THC treatment in rats treated
with PCP
NOR test
The eﬀect of chronic treatment with a low dose of THC
on cognitive impairment produced by PCP is shown in
Figure 5. All groups of rats spent equivalent time
exploring the identical objects (left and right) in the
familiarization phase (Figure 5a) without any changes
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Figure 3. Eﬀect of chronic phencyclidine (PCP) treatment on (a) CB1 receptor binding and (b) net CP-55,940-stimulated
[35S]GTPcS binding. (c) Autoradiograms of representative coronal sections of the amygdala and prefrontal cortex showing
alteration in CB1 receptor binding and net CP-55,940-stimulated [
35S]GTPcS binding, respectively. Bars indicate the mean¡S.E.M.
of at least four animals. * p<0.05, ** p<0.01, *** p<0.001 vs. controls (Student’s t test). Amy, amygdala ; VTA, ventral tegmental
area ; PFC, prefrontal cortex ; GP, globus pallidus ; Hip, hippocampus; SN, substantia nigra ; Cer, cerebellum.
604 D. Vigano et al.
in locomotion (Figure 5b). In the test phase, rats
treated with THC alone diﬀerentiated the familiar and
novel objects in a similar manner to controls as shown
by the signiﬁcant increase (p<0.01) in exploration
time of the new object compared with the familiar one
(Figure 5c). As expected PCP alone signiﬁcantly
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Figure 4. Eﬀect of chronic phencyclidine (PCP) treatment on endocannabinoid (AEA and 2-AG) content in the prefrontal cortex
and hippocampus. Data are expressed as the mean¡S.E.M at least four animals per group. * p<0.05 vs. vehicle (Student’s t test).
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Figure 5. Eﬀect of chronic D9-tetrahydrocannabinol (THC) treatment (0.5 mg/kg i.p.) on phencyclidine (PCP)-induced deﬁcit in
the novel object recognition (NOR) test. Panels (a) and (b) represent the exploration time of identical objects (a) and the number
of line crossing (b) during the familiarization trial. Panels (c) and (d) represent the exploration time of the familiar vs. novel
objects (c) and the discrimination index (d) during the test phase. The NOR test was performed 72 h after the last drugs injection.
Data are expressed as the mean¡S.E.M at least six animals per group. (c) ** p<0.01, *** p<0.001 vs. familiar object (Student’s
t test). (d) ** p<0.01 vs. vehicle ; + p<0.05 vs. PCP (one-way ANOVA followed by Bonferroni post-hoc comparison).
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reduced the DI (F3,26=18.40, p<0.0001, p<0.001 for
post-hoc comparison). The association THC+PCP
worsened this situation. In fact, during the test phase
the co-treated rats spent the same time in exploring
new and familiar objects (Figure 5c) and showed
a signiﬁcant impairment in recognition memory
vs. controls (x177%, F3,26=18.40, p<0.0001, p<0.001
for post-hoc comparison) which signiﬁcantly fell
when compared to PCP alone (x128%, F3,26=18.40,
p<0.0001, p<0.05 for post-hoc comparison) (Figure
5d). Thus, we demonstrated that prolonged exposure
of THC worsens the PCP-altered recognition memory.
CB1 receptor functionality
Table 1 summarizes the results of [3H]CP-55,940
receptor and CP-55,940-stimulated GTPcS autoradio-
graphic-binding assays performed in rats treated with
PCP alone and in association with THC. First, in the
group of rats receiving THC alone residual alterations
in CB1 receptor binding and functionality were still
present 72 h after the last injection. More precisely CB1
receptor binding was reduced in the cerebellum and a
signiﬁcant reduction in GTPcS binding was present in
the prefrontal cortex (x37%, F3,12=17.45, p<0.0001,
p<0.01 for post-hoc comparison) and cerebellum
(x36%, F3,12=3.581, p<0.05, p<0.05 for post-hoc
comparison). The picture of the PCP-treated group
was the same as described above (Figure 3), but when
THC was combined with PCP the desensitization of
CB1 receptors in the prefrontal cortex was much more
pronounced than that induced by PCP alone, reaching
a 69% decrease in respect to vehicle group
(F3,12=17.45, p<0.0001, p<0.001 for post-hoc com-
parison) and a 47% reduction when compared to
PCP or THC alone (F3,12=17.45, p<0.0001, p<0.05 for
post-hoc comparison) (Table 1). In contrast, in the
substantia nigra the THC co-treatment reversed the
impairment in CB1 functionality produced by PCP. In
fact, the CP-55,940-stimulated GTPcS was the same as
in the control group. In the other brain regions, the CB1
receptor system did not reveal diﬀerences between
PCP alone or THC+PCP.
Endocannabinoid levels
The eﬀect of THC co-treatment on PCP-induced alter-
ations in endocannabinoid content in the prefrontal
cortex is shown in Figure 6. Chronic THC alone pro-
duced a signiﬁcant reduction in AEA levels (x56%,
F3,10=4.854, p<0.05, p<0.05 for post-hoc comparison)
in respect to controls, whereas no changes in 2-AG
levels were observed. As previously described, PCP
alone did not signiﬁcantly aﬀect AEA levels but
produced a signiﬁcant increase in 2-AG (F3,12=5.752,
p<0.05, p<0.05 for post-hoc comparison). The co-
treatment provoked a further reduction in AEA
levels vs. either vehicle (x73%, F3,10=4.854, p<0.05,
p<0.01 for post-hoc comparison) or PCP (x64%,
F3,10=4.854, p<0.05, p<0.05 for post-hoc comparison),
Table 1. Eﬀect of chronic PCP and THC co-treatment on CB1 receptor binding (left) and net CP-55,940-stimulated
[35S]GTPcS binding (right). Data are expressed as the mean¡S.E.M. of at least four animals
[3H]CP-55,940 receptorbinding
(fmol/mg of tissue)
CP-55,940-stimulated GTPcS
(% of net stimulation)
Vehicle THC PCP THC+PCP Vehicle THC PCP THC+PCP
PFC 90.9¡5.1 92.17¡4.8 95.93¡4.8 103.5¡9.5 49¡3.5 ›30.8¡4.3** ›29¡2.3*** ›15.3¡3.2***+#
NAc 90.89¡5.3 89.97¡5.4 94.96¡6.5 91.08¡13.9 29.4¡4.8 21.3¡3.8 24.2¡3.8 16.8¡3.1
CPu 173¡7.8 182.8¡6.8 176.5¡5.6 191.8¡12.9 30.6¡4.9 27.3¡7.9 27.8¡4.2 21.2¡4.8
GP 312.4¡16.8 355.9¡18 312.1¡14.1 312.1¡22 69.6¡9 65.2¡14.9 ‹123.3¡18.3* 112.3¡18.8
Hypo 64.7¡3.5 60.63¡3.9 70.97¡3.9 60.97¡3.7 23.8¡5.5 22.1¡5.3 35.4¡5.4 38.5¡8.5
Thal 65.49¡2.7 67.25¡3.1 68.86¡2.6 60.8¡3.5 20¡4.7 19.8¡4.3 19.5¡4.9 22.6¡6.4
Amy 74.41¡4 85.46¡3.7 ‹86.12¡3.4* 73.2¡4.1 31.9¡4.9 48.6¡11.8 29.1¡4.7 22.6¡6.4
Hip 148.3¡4.9 153.2¡3.6 157.4¡3.7 149.3¡3.9 60.1¡4.2 47.2¡5.8 ›35.9¡3.3*** ›42.2¡2.8*
SN 444.1¡26.7 466.5¡27.9 440.8¡20.6 448.1¡18.4 186.4¡10.1 199.7¡17.34 ›132.5¡12.9** ‹179¡13.3+
VTA 51.58¡5.2 64.29¡4.1 ‹76.62¡6.1** 64.4¡3.8 27.4¡8.4 12.7¡3 16¡6.2 26.8¡1.6
Cer 255.1¡8.8 ›227.5¡8.9*++ 266.3¡6.6 ›214.7¡8.1**++ 71.2¡9 ›45.3¡6.6* ›43.1¡5.1* ›43.8¡8.8*
PFC, prefrontal cortex ; NAc, nucleus accumbens; CPu, caudate putamen ; GP, globus pallidus ; Hypo, hypothalamus ;
Thal, thalamus ; Amy, amygdala ; Hip, hippocampus ; SN, substantia nigra ; VTA, ventral tegmental area ; Cer, cerebellum.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle ; + p<0.05, ++ p<0.01, vs. PCP; # p<0.05 vs. THC (Bonferroni post-hoc test).
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whereas it reversed the PCP-induced increase in 2-AG
levels.
Discussion
Schizophrenia is associated with substantial cognitive
impairment that is severe and does not respond well
to the available treatments. Therefore, the develop-
ment and validation of animal models of cognitive
deﬁcit are crucial in clarifying the underlying neuro-
pathology and discovering new pharmacological
treatments for such deﬁcits. It is well known that
repeated PCP injections induce enduring cognitive
deﬁcits with particular relevance to schizophrenia
(Abdul-Monim et al., 2006, 2007 ; Amitai et al., 2007 ;
Grayson et al., 2007 ; Hashimoto et al., 2005 ; Idris et al.,
2005 ; Jentsch et al., 1997a,b ; Rodefer et al., 2005). In
the present study we have shown that chronic-
intermittent PCP injections produce a robust cognitive
deﬁcit in male Lister Hooded rats that persisted 72 h
after the last PCP injection. In the familiarization phase
of the NOR test, there was no diﬀerence in the level of
motivation, curiosity and interest among all the
groups studied as demonstrated by the lack of diﬀer-
ence in the total amount of time spent exploring two
identical objects. During the test phase, chronic PCP
reduced the ability to discriminate between novel and
familiar objects, thus showing an impairment associ-
ated with recognition memory deﬁcit. As previously
shown, this deﬁcit was improved by concomitant
chronic administration of clozapine (Grayson et al.,
2007 ; Hashimoto et al., 2005).
However, the major aim of the present work was
to verify whether the endocannabinoid system is in-
volved in this PCP model of cognitive dysfunction.
First, we explored the levels and functional coupling
of CB1 receptors in PCP-treated rats vs. controls.
We observed a signiﬁcant and localized increase in
receptor-binding sites in the amygdala and ventral
tegmental area whereas alterations in the CB1 receptor
eﬃciency were widely distributed through the brain.
GTPcS binding was altered in several brain areas im-
plicated in schizophrenia ; in particular, it was reduced
in the prefrontal cortex and hippocampus, increased
in the globus pallidus and decreased in the substantia
nigra and cerebellum. To the best of our knowledge
this is the ﬁrst study reporting changes in cannabinoid
receptor density and eﬃciency in an animal model of
schizophrenia. Previous studies have demonstrated
varying data on CB1 receptor binding in post-mortem
schizophrenia patients revealing diﬀerent results
depending on the speciﬁc brain region examined;
no changes in CB1 receptor density were reported in
the hippocampus and caudate putamen, whereas an
increase of CB1 receptor binding was found in cortical
areas in schizophrenia patients (Dean et al., 2001 ;
Deng et al., 2007 ; Koethe et al., 2007 ; Newell et al.,
2006 ; Zavitsanou et al., 2004). The discrepancy of
binding studies from animal and human assays could
be due to the unavoidable heterogeneity of humans
such as the interference of concurrent drug therapies
and the lack of systematic comparison with other
mental disorders in which endocannabinoid signalling
might also be dysregulated.
In addition, among all the brain areas showing al-
terations in CB1 receptor functionality, the reduction
observed here in the prefrontal cortex and hippocam-
pus appears very interesting due to the important role
of these regions in mediating cognitive functions
altered in NOR (Barker et al., 2007 ; Dere et al., 2007).
For this reason, in these cerebral areas we also as-
sessed the levels of the two main endocannabinoids,
AEA and 2-AG. We found in the prefrontal cortex of
PCP-treated rats a signiﬁcant elevation of 2-AG levels
and a 25% reduction in AEA (not reaching statistical
signiﬁcance). In contrast, no signiﬁcant diﬀerence in
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Figure 6. Eﬀect of chronic phencyclidine (PCP) and D9-tetrahydrocannabinol (THC) co-treatment on endocannabinoid (AEA and
2-AG) content in the prefrontal cortex. Data are expressed as the mean¡S.E.M at least four animals per group. * p<0.05, ** p<0.01
vs. vehicle ; + p<0.05, ++ p<0.01 vs. PCP (one-way ANOVA followed by Bonferroni post-hoc comparison).
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the level of either endocannabinoid was found in the
hippocampus. Despite several suggestions that the
endocannabinoid system might play a role in the
pathogenesis of schizophrenia, thus far no study has
addressed the question of whether or not the endo-
genous ligands are altered in the brain of animals
modelling schizophrenia. Previous biochemical ana-
lysis in humans has focused on the impact of schizo-
phrenia on serum and CSF levels of anandamide (De
Marchi et al., 2003 ; Giuﬀrida et al., 2004 ; Leweke et al.,
1999, 2007 ; Potvin et al., 2008). These studies agree
by suggesting that anandamide signalling may be
overactive in schizophrenia patients and that CSF
anandamide levels are negatively correlated with
psychotic symptoms. In parallel, Pryor (2000) pro-
posed a chronic over-release of 2-AG by platelets as a
causal factor of the cognitive deﬁcit associated with
negative schizophrenia symptoms, whilst more re-
cently, Potvin et al. (2008) after measuring plasma
levels in patients, did not ﬁnd changes in baseline
2-AG between schizophrenia patients and controls.
Our experimental data indicate that in the prefrontal
cortex of PCP-treated animals there is a dysregulation
of the endocannabinoid system characterized by a
signiﬁcant up-regulation of 2-AG levels coupledwith a
signiﬁcant reduction in CB1-stimulated GTPcS bind-
ing. The prefrontal cortex is hypoactive in schizo-
phrenia patients as shown by the reduced regional
cerebral blood ﬂow (Satoh et al., 1993 ; Weinberger
et al., 1986) and by the decreased glucose utilization
observed in schizophrenia patients (Andreasen et al.,
1992 ; Tamminga et al., 1992 ; Wolkin et al., 1992) as
well as in PCP abusers (Wu et al., 1991). The protocol
of Cochran and collaborators (2003) used in the
present study well reproduces the ‘hypofrontality’ as
evidenced by the decrease in the rates of glucose
utilization, reduction in markers of GABAergic inter-
neurons (parvalbumin mRNA expression) and the
deﬁcit in executive functions (Egerton et al., 2005,
2008 ; for review see Pratt et al., 2008). Our data indi-
cate that the endocannabinoid system is also involved
in this dysregulation and could play a role in the ob-
served cognitive impairments. In fact, the integrity of
the prefrontal cortex is essential in cognitive processes
and glutamate is indeed central to the activity of this
brain structure as most of the aﬀerents and eﬀerents
from the cortical area are glutamatergic in nature
(Moghaddam, 2002). It has been reported that PCP
administration, by blocking NMDA receptors present
in GABAergic chandelier cells, reduces GABA release
onto pyramidal neurons. The resultant disinhibition
increases pyramidal neuron activity thereby enhanc-
ing glutamate release (for review see McGuire et al.,
2008 ; Pratt et al., 2008). This mechanism may occur
locally at the prefrontal cortex and/or at regions with
ascending glutamatergic projections to this region.
The increase in glutamate may then lead to an excess-
ive stimulation of glutamate receptors, including
AMPA and kainate receptors which might cause cog-
nitive dysfunction (Moghaddam and Adams, 1998;
Moghaddam et al., 1997) and be responsible for the
elevation of 2-AG levels observed here, and found
previously to follow prefrontal cortex neuron stimu-
lation (Melis et al., 2004).
Several studies have reported that CB1 agonists can
reduce glutamatergic synaptic transmission in several
brain regions including the prefrontal cortex (Auclair
et al., 2000). Interestingly, the bulk of evidence
identiﬁes the endocannabinoid 2-AG as the most pro-
bable retrograde mediator at glutamatergic synapses
(Gerdeman et al., 2002 ; Robbe et al., 2002 ; Sjo¨stro¨m
et al., 2003 ; Straiker and Mackie, 2005). In particular,
2-AG is synthesized in the post-synaptic terminal of
glutamatergic synapses following activation of meta-
botropic mGluR5 glutamate receptors (Jung et al.,
2005) and is thought to suppress glutamate release
through activation of CB1 receptors located in pre-
synaptic glutamatergic axon terminals (Katona et al.,
2006). In light of these premises, we can speculate that
the increased level of 2-AG observed in the prefrontal
cortex of PCP-treated rats represents an adaptive re-
action aimed at reducing glutamatergic transmission
that, due to the plasticity of the endocannabinoid
system, also causes CB1 receptor internalization and
desensitization, as observed with several other types
of G-protein-coupled receptors.
Next, our interest was to evaluate the ability of
the main psychoactive ingredient of marijuana, THC,
to modulate the cognitive dysfunctions and neuro-
adaptations in the endocannabinoid system induced
by PCP. Low doses of chronic THC co-treatment
worsened PCP-induced cognitive impairment without
any eﬀect per se after a 72 h washout period. The
behavioural eﬀect of prolonged THC co-exposure
was in agreement with human studies supporting
the negative inﬂuence of cannabis on the expression
and course of schizophrenia cognitive impairment
(Coulston et al., 2007 ; D’Souza et al., 2005 ; Linszen
et al., 1994). In CB1 receptor-binding assays, chronic
THC decreased per se GTPcS coupling in the
prefrontal cortex and cerebellum in accordance with
several animal studies showing desensitization after
in-vivo repeated treatment with THC (for review see
Breivogel et al., 1999 ; Rubino et al., 2000b; Sim-Selley
and Martin, 2002). Furthermore, in this cerebral area,
prolonged THC exposure per se produced a robust
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decrease in AEA content. This result disagrees with a
previous report of Di Marzo and collaborators (2000)
where no changes in AEA levels in the cerebral cortex
were found after chronic THC treatment. Several
reasons can explain this discrepancy, including the
dose (0.5 mg/kg vs. 10 mg/kg), treatment regimen
(3 wk vs. 1 wk), withdrawal time (72 h vs. 2 h) and
selected cortical area (prefrontal cortex vs. cortex)
used in the two studies. Furthermore, a recent study
has shown that, similar to our present observations,
the local injection of a diﬀerent CB1 receptor agonist,
WIN55,212-2, reduces the release of AEA and en-
hances that of 2-AG, although from a diﬀerent brain
region, i.e. the hypothalamus (Be´quet et al., 2007).
More interestingly, the PCP+THC treatment pro-
duced a new scenario in the prefrontal cortex con-
sisting of a further and more intense CB1 receptor
desensitization, an additional reduction in AEA levels,
this time achieving statistical signiﬁcance, and a return
to control values of 2-AG tissue concentrations. Taken
together, THC co-exposure induces a new scenario in
which other elements of the endocannabinoid system
appear. The suppression of PCP-induced compensa-
tory increase of 2-AG, together with the worsened CB1
eﬃciency are likely to contribute to further enhance
glutamatergic neurotransmission, thus worsening the
cognitive performance. At the same time, the strong
decrease in AEA levels might contribute to the dys-
function of the dopaminergic system. In fact, it has
been suggested that AEA is implicated in the intrinsic
regulation of dopamine release, by acting retrogradely
on CB1 receptors located in a subset of dopaminergic
presynaptic terminals to limit dopamine release.
Consequently, the strong decrease we observed in
AEA content in the prefrontal cortex might produce a
robust increase in dopamine release as observed in
schizophrenia patients (McGuire et al., 2008) and this
might be associated with the worsened behavioural
performance, in accord with previous literature high-
lighting an antipsychotic-like role of AEA (Beltramo
et al., 2000 ; Giuﬀrida et al., 2004). Under this perspec-
tive, it is possible to speculate that AEA and 2-AG
might subserve diﬀerent physiological mechanisms
and might play diﬀerent roles in the pathophysiology
of schizophrenia. It is unsurprising that the endo-
cannabinoids play dissimilar functions in the brain
since several other studies have pointed out the
diﬀerent sensitivity of these two endogenous me-
diators to physiological or pathological processes in
rats (Giuﬀrida et al., 1999 ; Gonza´lez et al., 2000 ;
Kirkham et al., 2002 ; Valenti et al., 2004 ; Vigano` et al.,
2003, 2004 ; Rubino et al., 2008). There are several
possible reasons for this diﬀerent sensitivity of AEA
and 2-AG, e.g. to circadian rhythms or various patho-
logical conditions, not least the presence of diﬀerent
enzymes regulating their synthesis and degradation
(Di Marzo et al., 2001). Furthermore, it has been sug-
gested that under certain conditions, elevation of AEA
levels might decrease the biosynthesis of 2-AG via
activation of TRPV1 receptors (Maccarrone et al., 2008 ;
Di Marzo and Cristino, 2008), and this might explain
why also in this study the two compounds underwent
opposite changes following the same type of stimulus.
To sum up, our study is the ﬁrst to demonstrate
the occurrence and, possibly, the role of an apparent
maladaptation of the endocannabinoid system in a
cognitive schizophrenia-like model, and to show that
the aspects of cognitive performance are worsened
after prolonged THC injections. These ﬁndings would
be consistent with the theory that marijuana may be a
risk factor for development or worsening of the
schizophrenia disorder. If cannabinoid dysregulation
is considered as a potential cause of cognitive symp-
tomology or a setting event for the disorder, then it
may be possible to design therapeutic interventions to
address this issue by using the wide range of ligands
that directly or indirectly act on CB1 receptors and on
the enzymes that synthesize or inactivate the endo-
cannabinoids (Di Marzo and Petrosino, 2007).
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